Search | IOVS | ARVO Journals

View

Showing 1 – 13 of 13

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2018

A longitudinal study of the relationship between signs and symptoms in keratoconjunctivitis sicca

Jeffry Hogg; Dahlia Ismail; Jean-Sebastien Garrigue; Maëva Deniaud; Mourad Amrane; Francisco C Figueiredo

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):934. doi:

ARVO Annual Meeting Abstract July 2018

Topical Cyclosporine A 1 mg/mL Cationic Emulsion Yields Improvements in Signs of Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Results of the Phase III VEKTIS Study

Serge Doan; Andrea Leonardi; Mourad Amrane; Dahlia Ismail; Jesus Montero; Pasquale Aragona; Janos Nemeth; Dominique Brémond-Gignac

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5572. doi:

ARVO Annual Meeting Abstract June 2017

Topical Ciclosporin A 1 mg/mL Cationic Emulsion in the Treatment of Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Results of the Phase III VEKTIS Study

Andrea Leonardi; Serge Doan; Mourad Amrane; Dahlia Ismail; Jesus Montero; VVL Narasimha Rao; Janos Nemeth; Dominique Bremond-Gignac

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):541. doi:

Cornea April 2017

Correlation Between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye Disease

PDF

Françoise Brignole-Baudouin; Luisa Riancho; Dahlia Ismail; Maëva Deniaud; Mourad Amrane; Christophe Baudouin
TAGS: inflammatory markers, dry eye syndromes, hla-dr antigens, signs and symptoms
Invest. Ophthalmol. Vis. Sci.. 2017; 58(4):2438-2448. doi: 10.1167/iovs.15-16555

Includes: Supplemental Content

ARVO Annual Meeting Abstract September 2016

Pooling of two randomized Phase III clinical trials of ciclosporin 1 mg/mL cationic emulsion (CsA CE) as a treatment for severe keratitis in patients with dry eye disease (DED)

Elisabeth Messmer; Andrea Leonardi; Mourad Amrane; Dahlia Ismail; Francisco C Figueiredo; Christophe Baudouin

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2871. doi:

ARVO Annual Meeting Abstract September 2016

Topical ocular ciclosporin 1 mg/mL cationic emulsion in patients with dry eye with severe keratitis: Experience through the French early access program

Serge Doan; Pierre-Jean Pisella; Beatrice Cochener; Mourad Amrane; Dahlia Ismail; Christophe Baudouin; Marc Labetoulle

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2876. doi:

ARVO Annual Meeting Abstract September 2016

Safety and efficacy of ciclosporin 1 mg/mL cationic emulsion (CsA CE) over 12 months in patients with severe dry eye disease (DED) in the SANSIKA Phase III trial

Gysbert B Van Setten; Francisco C Figueiredo; Andrea Leonardi; Mourad Amrane; Jean-Sebastien Garrigue; Dahlia Ismail; Christophe Baudouin

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2865. doi:

ARVO Annual Meeting Abstract June 2015

Correlation between the Inflammatory Marker HLA DR and Signs and Symptoms in moderate to severe Dry Eye Disease

Christophe Baudouin; Hong Liang; Luisa RIANCHO; Dahlia Ismail; Maeva Deniaud; Mourad Amrane; Francoise Brignole-Baudouin

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):298. doi:

ARVO Annual Meeting Abstract June 2015

Patients with Moderate to Severe Dry Eye Disease in Routine Clinical Practice in the UK - Physician and Patient’s Assessments

Mourad Amrane; Alexandre CIVET; Alexandre Templier; Dian Kang; Francisco C Figueiredo

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4443. doi:

ARVO Annual Meeting Abstract March 2012

The Effect of Cyclokat® (preservative-free cyclosporine 0.1% cationic emulsion) on Dry Eye Disease Signs and Symptoms in Sjogren and non-Sjogren Patients with Moderate to Severe DED in a Phase III Randomized Clinical Trial

Ronald R. Buggage; Mourad Amrane; Dahlia Ismail; Maeva Deniaud; Michael A. Lemp; Christophe Baudouin

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):576. doi:

ARVO Annual Meeting Abstract March 2012

The Influence of Seasonality and Subtype in Vernal Keratoconjunctivitis (VKC) Patients in a Randomized Clinical Trial Investigating NOVA22007, a preservative-free cyclosporine cationic emulsion

Mourad Amrane; Andrea Leonardi; Dominique Bremond-Gignac; Maeva Deniaud; Dahlia Ismail; Christophe Baudouin; Ronald Buggage

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):4011. doi:

ARVO Annual Meeting Abstract April 2011

A Multicenter, Double-masked, Randomized, Parallel Group, Controlled Trial Of Efficacy And Tolerance Of NOVA22007 (Cyclosporine Cationic Emulsion) Versus Vehicle In Patients With Vernal Keratoconjunctivitis

Mourad Amrane; Dominique Bremond-Gignac; Christopher Baudouin; Andrea Leonardi; Maeva Deniaud; Ronald Buggage

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):6415. doi:

ARVO Annual Meeting Abstract April 2011

Poor Correlation Between Dry Eye Disease (DED) Signs and Symptoms in a Phase III Randomized Clinical Trial

Michael A. Lemp; Christopher Baudouin; Mourad Amrane; Dahlia Ismail; Jean Sebastien Garrigue; Ronald R. Buggage

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3821. doi:

Advertisement